Today, our CEO, Alexandria Forbes, Ph.D., will participate in a fireside chat at 1:00 p.m. ET at Chardan's 8th Annual Genetic Medicines Conference. Click through to register for the webcast. #GeneticMedicine https://lnkd.in/e8XtcxTH
About us
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.
- Website
-
http://www.meiragtx.com
External link for MeiraGTx
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- London/New York
- Type
- Public Company
- Founded
- 2015
- Specialties
- biotech, gene therapy, life sciences, rare disease, neurodegenerative disease, and inherited retinopathies
Locations
-
Primary
92 Brittania Walk
London/New York, N17NQ, GB
-
430 E29th Street
10th Floor
NEW YORK, New York 10016, US
Employees at MeiraGTx
Updates
-
MeiraGTx CEO and Founder Zandy Forbes will appear on the panel, "The Innovation Gap," at the World Medical Innovation Forum, hosted by Mass General Brigham in Boston this afternoon. The conversation will feature "a review of the future of viral vector manufacturing and the delivery of genetic medicines." Click through for more details on the panel and the conference. #WMIF2024 https://lnkd.in/gGePt_SZ
-
Next in our series of MeiraGTx #ICYMI highlights: Biotech2050 podcast's feature with MeiraGTx CEO and Founder Zandy Forbes. In the interview with host Rahul Chaturvedi, Dr. Forbes "shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company." The episode also details MeiraGTx’s cutting-edge approach to genetic medicines, focusing on the development of innovative therapies for non-inherited diseases. Click through to hear the podcast on Apple, Google, Spotify, Soundcloud, iHeart, or Amazon. https://lnkd.in/eKGHJN-t
-
ICYMI: Genetic Engineering & Biotechnology News (GEN) published a comprehensive profile of MeiraGTx and CEO Zandy Forbes entitled, "Switching Gene Therapy On and Off with a Pill." The article looks in-depth at MeiraGTx's riboswitch technology, but also details our company's manufacturing expertise, broad clinical pipeline, and capsid/promoter optimization. Click through for the full article by Gail Dutton, which according to GEN has been a top-read for its subscribers since first published this summer. https://lnkd.in/erZ6KiFi
-
At the BioCentury Inc. Grand Rounds conference in Nashville this afternoon, MeiraGTx CEO Zandy Forbes will participate in the panel, "The Heyday of AAV Engineering is Here: Will It Deliver?" The event also features a poster presentation by MeiraGTx scientists, "Novel Splicing Driven Gene Regulation Platform for Precise Dose Responsive Control of Gene and Cell Therapies," about our innovative riboswitch technology. View the poster at MeiraGTx's website: https://lnkd.in/e7V2TeeH
Slide 1
meiragtx.com
-
Zandy Forbes, CEO and co-founder of MeiraGTx, will appear today, June 12, at the Goldman Sachs 45th Annual Global Healthcare Conference. Dr. Forbes will discuss the latest innovations in genetic medicine from MeiraGTx, the company's end-to-end manufacturing and business models, and more. Tune in live to Dr. Forbes's comments at 2:40pm EST U.S. time today here: https://lnkd.in/enH38PS4
-
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease for which there is currently no cure. MeiraGTx is developing a first-in-class gene therapy candidate to potentially address both familial and sporadic ALS (>95% of ALS patients). Data resulting from MeiraGTx’s in vivo preclinical trials held in collaboration with leading ALS researchers provide strong evidence for the therapeutic potential of MeiraGTx’s genetic medicine (known as AAV-hUPF1). At the ALS Drug Development Summit in Boston today, Dr. Barbara Nguyen-Vu, Senior Director of Neuro at MeiraGTx, will discuss these data and insights in her presentation, “Demonstrating Success of a One-Dose Gene Therapy to Prevent Motor Neuronal Loss in Both Sporadic & Familial ALS: Preclinical Efficacy of AAV-hUPF1 Optimized for Clinical Translation with Improved Vector Genome and Novel CNS Capsid.” https://lnkd.in/gCHds7tt
Home - 3rd ALS Drug Development Summit 2024
als-drug-development.com
-
MeiraGTx reposted this
A fantastic piece of coverage in The Sunday Times featuring our client MeiraGTx's chief executive, Zandy Forbes. In a fascinating interview with Jim Armitage, Zandy talks about her life, her three careers and MeiraGTx's innovative business model. Read the full piece, here: https://lnkd.in/e54WqyfS
-
ICYMI: MeiraGTx’s gene therapy candidate for patients suffering from xerostomia (dry mouth due to radiation damage) was recently featured at the American Academy of Oral Medicine (AAOM), where Dr. Michael Brennan (Atrium Health, North Carolina) and colleagues presented positive data from MeiraGTx’s Phase 1 AQUAx study. Among other key findings: Patients 12 months out from treatment saw an increase in Unstimulated Whole Saliva Flow Rate of 112.8% from baseline. MeiraGTx’s Phase 2 AQUAx2 trial of the gene therapy is now enrolling eligible participants. Find more information and the full presentation here: https://lnkd.in/epEPuFmC
2024 American Academy of Oral Medicine (AAOM) Annual Conference | MeiraGTx
investors.meiragtx.com
-
Our CEO, Zandy Forbes, recently sat down with Brad Loncar at the NYSE for a segment of BiotechTV. Watch the full episode for more on our latest pipeline progress as well as our differentiated #GeneTherapy manufacturing capabilities.
𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: MeiraGTx's CEO Zandy Forbes on the gene therapy field and upcoming data her company will have over the coming quarters. She describes the investments MeiraGTx has made in manufacturing and how it is helped progress the various programs the company has ongoing. Full video: https://lnkd.in/g8rXWfcw BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent